Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 7Observational 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Prostatic Hyperplasia 2Neoplasms 1

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Dutasteride × Clear all
NCT00883909 2017-07-11

ARI103094-Follow-Up Study for REDUCE Study Subjects

GlaxoSmithKline

Completed
2,795 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms

NCT01337258 2017-05-30

Economic Analyses of the REDUCE Trial

GlaxoSmithKline

Completed
1 enrolled
Genitourinary

Neoplasms, Prostatic Hyperplasia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡